ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO646

Persistence of Signs and Symptoms in Treated Patients with C3 Glomerulopathy (C3G): Evidence from Real-World Data

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Lafayette, Richard A., Stanford University School of Medicine, Stanford, California, United States
  • Libby, Susanna, Adelphi Real World, Bollington, Cheshire East, United Kingdom
  • Pannagl, Katharina, Novartis Pharmaceuticals UK Ltd, London, United Kingdom
  • Ndife, Briana C., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
  • Smeets, Serge, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
  • Murphy, Kathleen, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
  • de Courcy, Jonathan, Adelphi Real World, Bollington, Cheshire East, United Kingdom
  • Proudfoot, Clare, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland

Complement 3 glomerulopathy (C3G) is a rare kidney disease, with an estimated incidence of 1-2/million/year. C3G is associated with a high risk of disease progression; approximately 50% of patients reach kidney failure within 10 years of diagnosis. This analysis aimed to describe C3G signs and symptoms (S&S) in treated patients.


Data were drawn from the Adelphi C3G Disease Specific Programme, a cross-sectional survey of C3G-treating nephrologists in US, EU5 (France, Germany, Italy, Spain, UK), China and Japan between August 2022 and April 2023. Nephrologists completed structured forms for consecutive patients presenting with C3G. The forms included demographics, C3G treatment history and clinical information including S&S.


111 nephrologists completed records for 385 C3G patients (US 100, EU5 189, China 60, Japan 36). Of the 288 receiving treatment at time of survey, median patient age was 41.0, 60% were men, 83% had C3 glomerulonephritis and 16% had dense deposit disease. 60% (173) of patients had been on treatment for <1 year, 21% (61) between 1-2 years and 19% (54) >2 years, median treatment duration was 43.2 weeks.
Despite currently receiving treatment, most patients had S&S at time of survey. This was consistent in patients with a longer treatment duration. Common S&S experienced were proteinuria, hypertension, fatigue, and hematuria (Table 1).
Around one third of patients had a CKD stage between 3b and 5, regardless of number of years on treatment.
Of those patients treated for >2 years, 44% had ≥1g proteinuria/day where reported.


Despite treatment, C3G S&S persist in the majority of patients. Proteinuria remains high in many patients, increasing risk of progression to kidney failure. This shows a need for targeted treatments for C3G.

Table 1: Current therapy and proteinuria levels by region


  • Commercial Support – Novartis Pharmaceuticals Corporation